Apple Stocks History: What’s Up with the Apple Downgrade? Info from Will Power of Robert W. Baird

Page 1 of 2

Apple Stocks History: A Leading Company Cheaper Than 90% Of Blue Chips... And It Recently Bounced 12%Earlier today, CNBC took a closer look at Apple Inc. (NASDAQ:AAPL)’s downgrade to neutral at Robert W. Baird.

So, who was the analyst behind the Apple Inc. (NASDAQ:AAPL) downgrade? That would be Will Power, senior analyst with Robert W. Baird.

When the interview gets underway, Power is asked if he feels “behind the curve?” Here is how he kicked things off:

“In all fairness, it is a bit painful. We have been defending the stock like many others on the way down here, on valuation, long term opportunity etc. You know, all of that said, we assessed the numbers and looked at consensus estimates and our real concern is that there is still downside to estimates and I think it is going to be tough for the stock to outperform in that environment over the next several months.”

After explaining why the downgrade was necessary and what he sees happening to Apple Inc. (NASDAQ:AAPL) shares over the next several months, the host follows up with a question prompting Power to talk about his main concerns:

“I think you are right. I think part of what we are trying to do here, Carl, is separate the stock from the company. I think as you look over the next two to three months, really the next several quarters, you’ve got further downside risk to estimates. You know, for the full year we’re close to $41 in earnings and the street is at $45. Even the March quarter, consensus is estimates are at the high end and our biggest concern is probably the June quarter.”

He then added the following about Apple Inc. (NASDAQ:AAPL):

Page 1 of 2

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!